21例原发乳腺淋巴瘤患者疗效及预后分析  

Clinical and prognostic analysis of 21 cases of primary breast lymphoma

作　　者：罗必华[1] 黄建清[2] 闫子勋[1] 赵维莅[1] 王黎[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,200025 [2]福建医科大学附属龙岩市第一医院

出　　处：《中华血液学杂志》2015年第4期277-281,共5页Chinese Journal of Hematology

基　　金：基金项目：国家自然科学基金（81101793、81325003）;上海市科委基金（14430723400、14140903100）;上海交通大学博士点创新基金（BXJ201312）

摘　　要：目的探讨原发性乳腺淋巴瘤（PBL）患者临床特征及治疗方法对预后的影响。方法对2003年至2013年所收治的21例PBL患者的临床资料进行回顾性分析。根据治疗方案的不同对患者进行分层分析，比较手术、预防性腰穿鞘注、利妥昔单抗应用对患者疗效和预后的影响。结果21例患者中6例行乳腺肿块穿刺活检术，2例行乳腺癌改良根治术，其余均行单纯乳腺肿块切除术后经病理学检查明确诊断。其中弥漫大B细胞淋巴瘤（DLBCL）17例，黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（MALT淋巴瘤）、滤泡性淋巴瘤、Burkitt淋巴瘤、皮下脂膜炎样T细胞淋巴瘤各1例。所有患者中仅1例肿块直径〉7cm（MALT淋巴瘤患者），其余均〈5cm。治疗后完全缓解（CR）19例，部分缓解和疾病进展各1例。中位随访14（6～75）个月，21例患者中l例死亡，3年总生存（OS）率为92．3％。化疗＋手术组（15例）患者的无进展生存（PFS）时间较单纯化疗组（6例）延长，差异有统计学意义（60个月对22个月，P=0．05），但两组患者的CR率和OS时间差异无统计学意义（P值均〉0．05）。20例CD20阳性患者中接受利妥昔单抗治疗者17例，与未接受的3例比较，CR率和PFS、OS时间差异均无统计学意义（尸值均〉0．05）。8例患者接受预防性腰穿鞘注治疗，与13例未接受者比较，中枢神经系统浸润发生率差异无统计学意义（P=0．381）。结论PBL以DLBCL多见，治疗效果较好，手术治疗仅为明确诊断，并不延长患者OS时间。PBL患者行预防性腰穿鞘注治疗不降低中枢神经系统浸润发生率。Objective To analyze the clinical features, therapeutic methods and prognosis of primary breast lymphoma （PBL）. Methods Twenty-one PBL patients treated in Ruijin Hospital from January 2003 to December 2013 were included in this study, with 17 diffuse large cell lymphoma （DLBCL）, 1 mucosa-associated lymphoid tumor （MALT）, 1 follicular lymphoma （FL）, 1 Burkitt lymphoma and 1 subcutaneous peniculitis T-cell lymphoma according to the WHO 2008 classification. Of 21 patients, only one patient with MALT has bulged tumor mass （〉7 cm）, other patients had tumor mass 〈 5 cm. Six patients had core needle biopsy of tumor, 2 modified radical operation, and others tumor excision for diagnosis. All the patients received chemotherapy. The impacts of surgery, rituximab and prophylaxis with lumbar puncture on the outcomes of patients were analyzed. Survival was estimated using Kaplan- Meier method and compared by log-rank test. All the results were analyzed by SPSS 10.0. Results Among 21 PBL patients, 19 achieved complete remission （CR）, 1 partial remission （PR） and 1 disease progression （PD）. Followed-up till July 2014, with median follow-up of 14 months （6-75 months）, only one patient died, with 3-year survival of 92.3%. Compared with chemotherapy alone, the progression-free survival （PFS） of combination therapy （surgery plus chemotherapy） was significant longer （P=0.015）,but without statistic differences of CR rate and overall survival （OS） between two groups. Among the 20 patients with CD20-positive tumor cells, 17 received Rituximab. PFS and OS, as well as CR rate of PBL had no difference between the treatment with and without Rimximab. The incidence of central nervous system （CNS） infiltration had no difference between patients vcith and without CNS prophylaxis through lumber-puncture and intrathecal injection. Conclusion With the common subtype of DLBCL, PBL patients had good outcome. Surgery, as a method to obtain tumor samples for diagnosis, could not prolong OS o

关 键 词：原发乳腺淋巴瘤 抗肿瘤联合化疗方案 手术 预后 

分 类 号：R737.9[医药卫生—肿瘤]